GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biotech company whose fate is closely tied to its heart failure drug. Its price chart reflects the long and arduous path to FDA approval and the subsequent struggle for commercial success in a competitive market.
Share prices of companies in the market segment - Pharma metabolism
Lexicon Pharmaceuticals focuses on the development and commercialization of drugs to treat diseases, using genetics to identify new targets. We classify it within the Pharmaceuticals (Metabolism) sector. The chart below shows the overall dynamics of this innovative segment.
Broad Market Index - GURU.Markets
Lexicon Pharmaceuticals is a biopharmaceutical company developing drugs to treat heart failure and other conditions. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Lexicon shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
LXRX - Daily change in the company's share price Lexicon Pharmaceuticals
Lexicon Pharmaceuticals' daily price change reflects the high risks of the biotech sector. Change_co is an instant reaction to news about clinical trials and FDA decisions. This indicator forms the basis for analysis in the innovative drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Lexicon Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with LXRX, which focuses on heart failure treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lexicon is a biopharmaceutical company specializing in drugs for the treatment of metabolic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Lexicon's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lexicon Pharmaceuticals
Lexicon Pharmaceuticals' year-to-date performance is the drama of a biotech company struggling to secure approval and commercialize its drugs. Its market cap over the past 12 months reflects FDA decisions on its heart failure and diabetes drugs, where a positive verdict can dramatically alter the company's fortunes, while a negative one can be a serious blow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative drugs. Its success depends on the commercialization of its approved heart failure drug. The chart below shows how its market share struggles and R&D performance impact its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexicon is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lexicon Pharmaceuticals
Lexicon, a biopharmaceutical company, is driven by its product cycle. The monthly fluctuations on the chart reflect sales data for its heart failure and diabetes medications, as well as clinical trial news, which drives its long-term growth.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company using its mouse genetics platform to discover and develop innovative drugs. Its sector dynamics, shown in the chart, reflect the high risks of R&D. Against this backdrop, it's possible to assess how regulatory decisions and the commercial launch of its drugs for heart failure and diabetes affect its prospects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexicon is a biopharmaceutical company whose future depends on the results of clinical trials. Its shares don't move in sync with the market, but rather jump around after important news. The chart clearly demonstrates that LXRX's monthly fluctuations are a response to internal events, not to overall investor sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops drugs to treat heart failure and diabetes. Its weekly stock price, typical of biotech companies, is volatile and heavily dependent on FDA decisions and clinical trial data.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Lexicon, like the entire biotech sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks that impact investor interest in the entire sector. The chart shows how the company is tracking this overall biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lexicon Pharmaceuticals is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
LXRX - Market capitalization of the company Lexicon Pharmaceuticals
The Lexicon Pharmaceuticals chart shows the roller coaster of biotech development. Its market cap reacts sharply to FDA news and clinical trial results. It's a story of the long and risky battle to bring new drugs to market for diabetes and heart failure.
LXRX - Share of the company's market capitalization Lexicon Pharmaceuticals within the market segment - Pharma metabolism
Lexicon Pharmaceuticals is building its market share by focusing on drug development based on genetic research. Its market capitalization reflects both the risks and potential of its approach, particularly following the approval of its drug for heart failure.
Market capitalization of the market segment - Pharma metabolism
Lexicon Pharmaceuticals uses genetics to create drugs. How big is this arena? The chart below shows the total market capitalization of the metabolism-focused pharmaceutical sector. Its dynamics reflect the enormous investment and hopes associated with finding new approaches to treating diabetes and heart failure.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Lexicon Pharmaceuticals chart reveals the dramatic story of drug development. Its market cap reflects the long and arduous journey to approval of a drug to treat heart failure in diabetics. It's a chart full of the ups and downs typical of biotech, where persistence can ultimately pay off.
Book value capitalization of the company, segment and market as a whole
LXRX - Book value capitalization of the company Lexicon Pharmaceuticals
For Lexicon Pharmaceuticals, book value is its tangible foundation: R&D centers, rights to developed drugs, and financial reserves for their commercialization and further research. The chart below shows how this scientific and financial capital was formed and changed.
LXRX - Share of the company's book capitalization Lexicon Pharmaceuticals within the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company whose tangible assets include large research centers and laboratories. It was here, through genetic research, that its drugs were discovered and developed. The chart shows the share of this knowledge-intensive R&D infrastructure the company controls in its field.
Market segment balance sheet capitalization - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. As a commercial company, Lexicon invests not only in R&D but also in the infrastructure to market its products.
Book value of all companies included in the broad market index - GURU.Markets
Lexicon Pharmaceuticals' core assets include R&D centers and laboratories for the discovery and development of new drugs. The chart below shows how the company built its scientific and physical capital to bring its molecules to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lexicon Pharmaceuticals
Lexicon Pharma's book value is its research laboratories. However, the market doesn't value these, but rather the potential revenue from its unique, patent-protected drugs. The premium to book value is a direct reflection of investors' faith in the commercial success of these drugs. The chart below is a cardiogram of market expectations, showing how they rose and fell with each sales announcement and regulatory decision.
Market to book capitalization ratio in a market segment - Pharma metabolism
Lexicon Pharmaceuticals develops drugs to treat metabolic and cardiovascular diseases. Its valuation depends on the approval and commercial success of its drugs. The chart shows how its market capitalization, based on expectations, relates to its assets.
Market to book capitalization ratio for the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs that target novel therapeutic targets. Its valuation, compared to the average, is volatile and dependent on clinical trial news. Investors are betting that its unique scientific approach will lead to a successful drug.
Debts of the company, segment and market as a whole
LXRX - Company debts Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is focused on the development and commercialization of its drugs. This chart reflects its financial history, including both successful launches and clinical trial failures. The company utilizes various forms of financing, including partnerships and equity issuance, to bring its drugs to market.
Market segment debts - Pharma metabolism
Lexicon Pharmaceuticals is focused on developing small-molecule drugs. The company has encountered difficulties obtaining approval for its key drugs. This chart shows how its debt policy reflects these regulatory setbacks and how it manages its capital to fund further research and efforts to bring its products to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops and commercializes drugs. The process of bringing a new drug to market is long, expensive, and risky. This chart shows the extent to which the company uses debt to finance clinical trials and marketing efforts. It measures its financial risk to profitability.
Market segment debt to market segment book capitalization - Pharma metabolism
Lexicon Pharmaceuticals focuses on developing drugs to treat metabolic and cardiac diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical trials leading to drug approval and market launch.
Debt to book value of all companies in the market
Lexicon Pharmaceuticals focuses on developing drugs for metabolic and cardiovascular diseases. Biopharmaceutical research is a high-cost marathon. This graph of total market debt shows the overall risk appetite and helps assess the company's ability to raise funds to complete clinical trials.
P/E of the company, segment and market as a whole
P/E - Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is focused on developing innovative small-molecule drugs. This chart reflects the high risks and volatility of the biotech sector. Its performance depends entirely on clinical trial results and regulatory approval or rejection decisions by regulatory authorities (the FDA).
P/E of the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company that uses its unique genetic research platform to discover and develop innovative drugs for a wide range of diseases. This chart shows the average valuation for the pharmaceutical sector, reflecting the premium investors are willing to pay for science-intensive drug discovery platforms.
P/E of the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs to treat heart failure and other conditions. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of heart disease and diabetes. This graph reflects the expected commercial success of its approved drug, Inpefa. The company's valuation depends on how successfully it can launch its product into the competitive cardiac market.
%20P%2FE%20Lexicon%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lexicon-Pharmaceuticals&v=1772624088307 "Chart of the company's future (projected) P/E Lexicon Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma metabolism
Lexicon Pharmaceuticals is focused on developing and commercializing drugs to treat metabolic diseases such as diabetes and heart failure. This chart reflects expectations for its clinical and commercial success. Comparing its profitability forecasts with the sector reveals whether investors believe its drugs have the potential to become blockbusters.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772624088417 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Lexicon Pharmaceuticals is focused on developing drugs to treat diseases with significant unmet needs. It is a high-risk biotech company. This overall risk appetite chart determines how willing investors are to fund companies whose success depends on one or two key clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624088432 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs. Its financial performance depends on the market success of its products, particularly the approval and sales of drugs for the treatment of heart failure and diabetes. This graph shows the path from development to revenue generation.
Profit of companies in the market segment - Pharma metabolism
Lexicon Pharmaceuticals focuses on developing drugs that utilize a novel approach to treating diseases through gene inhibition. The company operates in a high-risk, cutting-edge field of science. The profitability curve for the metabolism pharmaceuticals sector reflects the degree of investor confidence in new therapeutic targets and their willingness to fund lengthy and expensive clinical trials.
Overall market profit
Lexicon Pharmaceuticals discovers and develops innovative drugs for the treatment of various diseases. The company focuses on new mechanisms of action, which can lead to the creation of breakthrough drugs. Its success depends on the results of clinical trials and exemplifies how scientific innovation can drive growth in the pharmaceutical industry.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of heart disease and diabetes. This graph reflects the expected commercial success of its recently approved drug. Profitability depends on how successfully the company brings it to a competitive market.
%20profit%20of%20the%20company%20Lexicon%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lexicon-Pharmaceuticals&v=1772624088535 "Graph of future (projected) profit of the company Lexicon Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Lexicon Pharmaceuticals is engaged in the discovery and development of small-molecule drugs. This chart illustrates profitability forecasts for the biotech sector. It helps understand how the success or failure of one or two key drugs in clinical trials impacts the company's prospects within the broader innovation industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772624088553 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Lexicon Pharmaceuticals' profit forecast hinges on the successful launch and sales of its new heart failure drug. This chart reflects investor expectations regarding the drug's commercial potential and the company's ability to compete with drugs from major pharmaceutical companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624088572 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lexicon Pharmaceuticals
Lexicon Pharmaceuticals focuses on developing small-molecule drugs. Its revenue can be volatile and depends on the success of individual drugs. This chart shows a valuation that reflects both current sales and investor expectations regarding the approval and commercial launch of new drugs.
P/S market segment - Pharma metabolism
Lexicon Pharmaceuticals focuses on the development and commercialization of drugs that target novel therapeutic targets. The company's revenue depends on the market success of its drugs. This chart shows the average pharmaceutical industry rating, helping to assess how the market perceives Lexicon's scientific innovations and their potential for future revenue generation.
P/S of the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cardiac and metabolic diseases. Its success depends on the approval and commercialization of its products. This chart, showing Lexicon's average revenue estimates, helps understand how investors assess the risks and potential rewards of its clinical programs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is focused on developing small-molecule drugs. The company's success depends on the approval and commercial launch of its candidates. This graph reflects investor expectations for future revenues that may arise if its heart failure and diabetes drugs receive regulatory approval.
%20P%2FS%20Lexicon%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lexicon-Pharmaceuticals&v=1772624088729 "The graph of the company's future (projected) P/S Lexicon Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cardiac and metabolic diseases. This chart compares market expectations for its future revenue with other pharmaceutical companies in the metabolism field. The valuation reflects investor expectations for the commercial success of its approved drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772624088748 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs to treat heart disease and diabetes. Its future depends on the approval and successful launch of new drugs. The company's potential to offer innovative treatments is part of the overall optimism about medical progress, reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624088766 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lexicon Pharmaceuticals
Lexicon Pharmaceuticals specializes in drug development using genetics to discover new therapeutic targets. This chart will reflect revenue from sales of its approved drugs or partnerships, demonstrating the commercial success of its scientific approach.
Sales of companies in the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company using its mouse genome platform to discover and develop innovative drugs. The company focuses on drugs for the treatment of heart failure and diabetes. This chart shows overall sales in the pharmaceutical sector, reflecting the potential for new therapeutic approaches to treating common diseases.
Overall market sales
Lexicon Pharmaceuticals focuses on developing drugs that utilize a novel mechanism of action—SGLT1 and SGLT2 inhibition—for the treatment of heart failure and diabetes. This overall economic activity chart is important for Lexicon through the lens of funding and partnerships. A successful drug launch requires significant resources and a healthy economic environment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lexicon Pharmaceuticals
Lexicon Pharmaceuticals focuses on developing drugs to treat metabolic and cardiac diseases. The company's future revenue depends on the commercial success of its approved drugs and the results of clinical trials of new candidates. This chart shows analysts' assessments of the market potential of the company's products.
%20sales%20of%20the%20company%20Lexicon%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lexicon-Pharmaceuticals&v=1772624088998 "Schedule of future (projected) sales of the company Lexicon Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma metabolism
Lexicon Pharmaceuticals develops drugs to treat metabolic diseases and heart failure. This chart shows projected revenues for the entire pharmaceutical sector. While it provides an overview of overall trends, for Lexicon, the approval and commercial success of its target drugs is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772624089019 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of metabolic diseases and heart failure. Its success depends on the approval and commercial launch of its drugs. This schedule, reflecting the state of the economy, affects the healthcare system's ability to pay for new, potentially expensive drugs, which is important for Lexicon's future growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624089131 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops and markets drugs for the treatment of metabolic diseases. This chart shows the company's financial path from development to commercialization. Profitability depends on sales volumes of approved drugs, which must cover not only current but also past multi-million dollar research costs.
Market segment marginality - Pharma metabolism
Lexicon Pharmaceuticals focuses on drug development using a genetic approach to discover new targets. This chart reflects the company's operational structure during the commercialization and further research phases. It allows for comparison with other biotech companies, showing how it balances sales of approved drugs with investments in the future.
Market marginality as a whole
Lexicon Pharmaceuticals specializes in the discovery and development of small-molecule drugs. The company's profitability depends on the success of its clinical trials and the commercialization of its products. This overall market return chart serves as a contrast to the biotech sector, where scientific innovation and regulatory approval are the primary factors determining a company's financial success.
Employees in the company, segment and market as a whole
Number of employees in the company Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs discovered using its genetics platform. This graph shows the team of scientists and clinicians. The headcount dynamics reflect the ups and downs associated with clinical trial results and FDA approval.
Share of the company's employees Lexicon Pharmaceuticals within the market segment - Pharma metabolism
This figure reflects Lexicon Pharmaceuticals' scientific focus. The company's pharmaceutical workforce is focused on developing drugs discovered using its genome analysis platform. This team of scientists strives to create innovative drugs for diseases such as heart failure and diabetes, based on a deep understanding of genetics.
Number of employees in the market segment - Pharma metabolism
Lexicon Pharmaceuticals focuses on drug development, using genetics to discover new therapeutic targets. This science-intensive approach enables the creation of innovative drugs. This graph illustrates how much modern pharmaceuticals rely on breakthroughs in genetics, driving demand for geneticists and bioinformatics specialists.
Number of employees in the market as a whole
Lexicon Pharmaceuticals, Inc. is a commercial-stage biotechnology company. Its success depends on sales of approved drugs and research results. This overall employment schedule affects it indirectly, through patients' ability to pay for treatment through insurance, which is backed by stable employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing small-molecule drugs. This chart reflects the company's valuation with products at various stages. An increase in this valuation can indicate successful approval of a new drug, which sharply increases the market valuation, while the research staff remains relatively stable.
%20of%20the%20company%20Lexicon%20Pharmaceuticals%20(LXRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lexicon-Pharmaceuticals-LXRX&v=1772624089586 "Chart of market capitalization per employee (in thousands of dollars) of the company Lexicon Pharmaceuticals (LXRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Lexicon Pharmaceuticals is engaged in the discovery and development of innovative drugs. As with any biotech company, its value is determined by its pipeline. This chart illustrates the enormous potential value investors see in the company's developments, which could become new standards of treatment for various diseases.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772624089607 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of heart failure and diabetes. This chart reflects investor valuations of its R&D pipeline. The high cost per employee reflects a bet on its drugs successfully completing clinical trials and receiving regulatory approval.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624089667 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company that has secured approval for a drug to treat heart failure in diabetics (Inpefa) and diarrhea in patients with carcinoid syndrome. This chart shows how successfully the company is bringing these drugs to market. Earnings per employee will increase if sales cover R&D costs.
%20Chart%20Lexicon%20Pharmaceuticals%20(LXRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lexicon-Pharmaceuticals-LXRX&v=1772624089743 "Company Profit Per Employee (in thousands of dollars) Chart Lexicon Pharmaceuticals (LXRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Lexicon Pharmaceuticals develops small-molecule drugs, focusing on the treatment of heart failure and diabetes. During the commercialization phase of a new drug, this chart shows the effectiveness of its sales efforts. It serves as a benchmark for assessing how successfully Lexicon is bringing its product to a market dominated by large pharmaceutical companies using its sales force.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772624089754 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on developing SGLT1/2 inhibitors for the treatment of heart failure and diabetes. This is an R&D business. This graph (likely unprofitable) reflects their path to commercialization. The costs of scientists and clinical trials are high. If their drug is approved, this figure should increase sharply due to sales revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624089756 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of metabolic and cardiovascular diseases. This chart reflects the company's activities in the commercialization stage. Revenue per employee growth is driven by successful sales of recently approved drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lexicon-Pharmaceuticals-LXRX&v=1772624089785 "Sales chart per company employee Lexicon Pharmaceuticals (LXRX)")
Sales per employee in the market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company developing drugs to treat metabolic diseases (e.g., diabetes). This chart shows the average revenue per employee in this segment. It serves as a comparison to a sector where productivity depends on the success of R&D and the commercialization of new drugs.
Sales per employee for the market as a whole
Lexicon Pharmaceuticals is a biopharmaceutical company focused on drug development using its expertise in genetic engineering. They have approved products. This metric reflects how their R&D and sales teams generate revenue from their proprietary drugs targeting specific therapeutic areas (e.g., diabetes).
Short shares by company, segment and market as a whole
Shares shorted by company Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals is a biotech company. The bearish sentiment seen on this chart is often linked to the commercial success of its drugs. Bears may doubt that a new drug (for example, one for heart failure) will be able to compete with established blockbusters from pharma giants (Lilly, Novo).
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lexicon-Pharmaceuticals-LXRX&v=1772624089841 "Short Shares Chart for the Company Lexicon Pharmaceuticals (LXRX)")
Shares shorted by market segment - Pharma metabolism
Lexicon Pharmaceuticals is a biotech company that has secured approval for its drug for the treatment of heart failure in diabetics (Inpefa). This chart reflects the overall sentiment in the sector. It reflects investor skepticism about the ability of small biotech companies to successfully commercialize their drugs in highly competitive markets.
Shares shorted by the overall market
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on metabolic diseases. A recent drug approval offers hope, but the company remains in a high-risk zone. This chart measures the overall level of fear. When panic mounts, investors avoid delving into the details of approvals and sell off the entire biotech sector.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals is a biotech whose fate hinges on a single drug (Sotagliflozin) for the treatment of heart failure. This chart measures investor confidence in this single product. It shows when the stock is "overbought" on expectations of FDA approval or "oversold" on news of delays or a weak launch.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lexicon-Pharmaceuticals-LXRX&v=1772624090152 "RSI 14 indicator chart for the company's stock Lexicon Pharmaceuticals (LXRX)")
RSI 14 Market Segment - Pharma metabolism
Lexicon Pharmaceuticals is a biopharmaceutical company specializing in developing drugs to treat metabolic diseases. Their recent success was the approval of Inpefa (sotagliflozin) for heart failure. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Lexicon Pharma (LXRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LXRX (Lexicon Pharmaceuticals)
Lexicon (LXRX) is a biopharmaceutical company focused on treating metabolic diseases and heart failure. This chart shows the average target price. It reflects the collective analyst consensus on the commercial success of its new drug, Inpefa, and its ability to gain market share in the competitive cardiac market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LXRX-Lexicon-Pharmaceuticals&v=1772624090240 "A chart showing analyst consensus forecasts for the expected stock price. LXRX (Lexicon Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price LXRX (Lexicon Pharmaceuticals)
Lexicon is a biotech company focused on INPEFA (Sotagliflozin), a unique dual SGLT1/2 inhibitor approved for the treatment of heart failure (HF). This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in INPEFA's commercial success in the highly competitive HF market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LXRX-Lexicon-Pharmaceuticals&v=1772624090253 "A chart showing the difference between the consensus forecast and the actual stock price. LXRX (Lexicon Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Lexicon Pharmaceuticals achieved success with Inpefa (sotagliflozin), approved for the treatment of heart failure. This chart shows analysts' overall expectations for the metabolic diseases sector. It reflects whether experts believe the company can compete with giants like Lilly and Novo in this vast market.
Analysts' consensus forecast for the overall market share price
Lexicon is a biopharmaceutical company focused on developing drugs for metabolic diseases (e.g., diabetes) and heart failure. This chart shows overall market sentiment. For Lexicon, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences funding for their long-term clinical trials. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company focused on commercializing its drug (Sotagliflozin), which targets diabetes and heart failure. This chart is a barometer of their launch. It likely reflects the rate of prescription growth and the market's confidence that their drug (with its unique dual SGLT1/2 mechanism) will be able to gain market share in this highly competitive market.
AKIMA Market Segment Index - Pharma metabolism
Lexicon (LXRX) is a biotech company that (after years of R&D) achieved success by receiving FDA approval for its drug Sotagliflozin (Inpefa), a first-in-class SGLT1/2 inhibitor for the treatment of heart failure. This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does Lexicon's breakthrough (new class) R&D model differentiate it from the average pharma company?
The AKIM Index for the overall market
Lexicon Pharmaceuticals is a biotech company using genetics for drug discovery. It is commercializing a heart failure drug (Sotagliflozin). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this product launch story compares to overall economic trends.
